Combined antiviral-immunosuppressive treatment in human T-lymphotrophic virus 1-Sjögren-associated myelopathy.

Détails

ID Serval
serval:BIB_54BD6954B2D5
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
Combined antiviral-immunosuppressive treatment in human T-lymphotrophic virus 1-Sjögren-associated myelopathy.
Périodique
Archives of neurology
Auteur⸱e⸱s
Pot C., Chizzolini C., Vokatch N., Tiercy J.M., Ribi C., Landis T., Perren F.
ISSN
0003-9942 (Print)
ISSN-L
0003-9942
Statut éditorial
Publié
Date de publication
09/2006
Peer-reviewed
Oui
Volume
63
Numéro
9
Pages
1318-1320
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Résumé
In several studies, antiretroviral drugs (principally zidovudine) have been used with success in the treatment of myelopathy associated with human T-lymphotrophic virus 1 (HTLV-1) (tropical spastic paraparesis-HTLV-1-associated myelopathy). The retrovirus HTLV-1 has been implicated as a causative agent of Sjögren syndrome (SS) in clinical reports and murine experiments. Moreover, a recognized complication of primary SS is a myelopathy, which has been shown in case reports to respond to immunosuppressive treatment.
To describe a patient with a rapidly progressive, extensive myelopathy with evidence of HTLV-1 infection and SS (probably secondary to HTLV-1) in whom we achieved spectacular therapeutic success using combined immunosuppressive and antiviral therapy.
Case report.
University hospital. Patient A young Haitian woman diagnosed with HTLV-1 and SS developed extensive myelopathy leading to severe disability.
Clinical and radiological improvement.
Spectacular radiological and clinical recovery as well as stabilization were achieved with combined antiviral and immunosuppressant treatment. Follow-up at 2 years showed no signs of relapse.
Both tropical spastic paraparesis-HTLV-1-associated myelopathy and Sjögren myelopathy are potentially very disabling. Rapidly progressive myelopathy secondary to SS necessitates the introduction of immunosuppressant therapies. The presence of HTLV-1 may confer the necessity to add antiviral therapy.
Mots-clé
Adenine/analogs & derivatives, Adenine/therapeutic use, Antiviral Agents/therapeutic use, Drug Therapy, Combination, Female, HTLV-I Infections/complications, HTLV-I Infections/drug therapy, HTLV-I Infections/radiotherapy, Humans, Immunosuppressive Agents/therapeutic use, Lamivudine/therapeutic use, Magnetic Resonance Imaging/methods, Methylprednisolone/therapeutic use, Middle Aged, Organophosphonates/therapeutic use, Prednisone/therapeutic use, Radiography, Sjogren's Syndrome/complications, Sjogren's Syndrome/diagnostic imaging, Sjogren's Syndrome/drug therapy, Tenofovir
Pubmed
Web of science
Open Access
Oui
Création de la notice
21/08/2018 17:17
Dernière modification de la notice
01/07/2020 11:48
Données d'usage